Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02921269 · ClinicalTrials.gov registry record · Phase 2
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 study of Cervical Adenocarcinoma and Cervical Adenosquamous Carcinoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
- 20
- Study locations
NCT02921269 is a Phase 2 study of Cervical Adenocarcinoma and Cervical Adenosquamous Carcinoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 11 participants, below the 123-participant average among 13 other Cervical Adenocarcinoma trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT02921269, a Phase 2 study of Cervical Adenocarcinoma and Cervical Adenosquamous Carcinoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with cervical cancer that has come back, remains despite treatment, or has spread to other places in the body. Monoclonal antibodies, such as atezolizumab and bevacizumab, may shrink tumor cell and interfere with the ability of tumor cells to grow and spread.
Conditions Studied
Interventions
- DRUG Atezolizumab
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Bevacizumab
Study Locations (20)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Brigham and Women's Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
California
- Los Angeles County-USC Medical Center - Los Angeles
- USC / Norris Comprehensive Cancer Center - Los Angeles
- Keck Medical Center of USC Pasadena - Pasadena
Georgia
- Emory University Hospital Midtown - Atlanta
- Emory University Hospital/Winship Cancer Institute - Atlanta
New Jersey
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital - New Brunswick
- Rutgers Cancer Institute of New Jersey - New Brunswick
Colorado
- University of Colorado Hospital - Aurora
Florida
- Moffitt Cancer Center - Tampa
Kentucky
- University of Kentucky/Markey Cancer Center - Lexington
Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2017-03-10 |
| Est. Completion | 2021-01-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02921269
The ClinicalTrials.gov registry entry for NCT02921269 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 123-participant average among 13 other Cervical Adenocarcinoma trials with a reported enrollment target (91% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Cervical Adenocarcinoma appearing as the primary indexed condition, and to 3 interventions - of which Atezolizumab is the first listed.
NCT02921269 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Massachusetts, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT02921269 about?
NCT02921269 is a clinical study titled "Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer". This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with cervical cancer that has come back, remains despite treatment, or has spread to other places in the body. Monoclonal antibodies, such as atezolizumab and bevacizumab, may shrink tumor cell and interfere ...
What is the current status of trial NCT02921269?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2017-03-10. Estimated completion is 2021-01-13.
What conditions does trial NCT02921269 study?
This clinical trial studies the following conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Recurrent Cervical Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IV Cervical Cancer AJCC v6 and v7.
What interventions are being tested in trial NCT02921269?
The interventions under investigation include: Atezolizumab (DRUG), Laboratory Biomarker Analysis (OTHER), Bevacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02921269?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02921269 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer
COMPLETED · Phase 2
-
ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer
COMPLETED · Phase 2
-
Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer
COMPLETED · Phase 2
-
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
COMPLETED · Phase 2
-
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.